ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech firm Agios picks Fouse as CEO

by Lisa M. Jarvis
September 7, 2018 | APPEARED IN VOLUME 96, ISSUE 36

 

09636-buscon16-fouse.jpg
Credit: Agios
Fouse

Jacqualyn Fouse has been named the next CEO of Agios Pharmaceuticals, a Cambridge, Mass.-based biotech firm. Effective Feb. 1, 2019, Fouse takes over for David Schenkein, who will become head of Agios’s board. Over the past decade, Schenkein has guided Agios as it shifted from a research organization to a biotech with two approved cancer drugs. Fouse, who was earlier president of Celgene, had been floated as a candidate for Gilead Sciences’ top job. Fouse will be one of the first women to helm a revenue-generating biotech firm.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment